^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    oxaliplatin

    i
    Other names: 1 OHP, 1670 RB, L OHP, NSC 266046, PR 54780, RP 54780, SR 96669, 1670 RB7
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, DNA cross linking agent
    Related drugs:
    1d
    Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, Jeeyun Lee | N=50 --> 100
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 positive • CLDN18.2 positive
    |
    Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    1d
    Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, National Cancer Institute (NCI) | N=240 --> 2 | Trial completion date: Oct 2027 --> Jun 2027 | Trial primary completion date: Oct 2027 --> Jan 2026
    Enrollment change • Trial completion date • Trial primary completion date • MSI-H • dMMR
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    1d
    CRITⅡ: SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC (clinicaltrials.gov)
    P3, N=204, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker • pMMR
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    1d
    GALNT5 drives colorectal cancer progression and chemoresistance via PI3K/Akt/ABCC1 axis. (PubMed, J Cancer Res Clin Oncol)
    GALNT5 facilitates malignant progression in CRC by promoting O-GalNAc glycosylation of EGFR and thereby activating the PI3K/Akt pathway, and confers resistance to L-OHP and 5FU through upregulation of ABCC1. These findings suggest GALNT5 as a potential diagnostic biomarker and a promising therapeutic target for overcoming chemoresistance in CRC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ABCC1 (ATP Binding Cassette Subfamily C Member 1)
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    1d
    Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer (clinicaltrials.gov)
    P2, N=17, Terminated, University of Southern California | Active, not recruiting --> Terminated; Insufficient Accrual
    Trial termination
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    1d
    Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer (clinicaltrials.gov)
    P2, N=64, Recruiting, Virginia Commonwealth University | Trial completion date: Jan 2033 --> Jan 2032 | Trial primary completion date: Jan 2028 --> Jan 2030
    Trial completion date • Trial primary completion date
    |
    oxaliplatin
    1d
    A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (clinicaltrials.gov)
    P1/2, N=222, Not yet recruiting, Genfleet Therapeutics (Shanghai) Inc.
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
    |
    KRAS mutation • RAS mutation
    |
    Erbitux (cetuximab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium
    2d
    Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=66, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    capecitabine • oxaliplatin • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    2d
    Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases (clinicaltrials.gov)
    P3, N=332, Not yet recruiting, Peking University
    New P3 trial
    |
    Tyvyt (sintilimab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701)
    2d
    Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer (clinicaltrials.gov)
    P1/2, N=186, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • HER-2 expression
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    2d
    A Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P3 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • trastuzumab rezetecan (SHR-A1811) • leucovorin calcium • levoleucovorin calcium
    2d
    Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery (clinicaltrials.gov)
    P2, N=30, Completed, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Completed | Trial completion date: Aug 2024 --> Sep 2025 | Trial primary completion date: Mar 2024 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • Zepsun (donafenib)